Tramadol News and Research

RSS
New NPS information on dextropropoxyphene: recommendations and alternatives

New NPS information on dextropropoxyphene: recommendations and alternatives

Ampio announces two new European patents for Zertane combination therapy

Ampio announces two new European patents for Zertane combination therapy

Medical websites provide harmful information about postherpetic neuralgia treatments

Medical websites provide harmful information about postherpetic neuralgia treatments

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Cipher net revenue decreases to $0.7 million for Q2 2011

Cipher net revenue decreases to $0.7 million for Q2 2011

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Cipher first quarter net revenue decreases to $0.7 million

Cipher first quarter net revenue decreases to $0.7 million

Labopharm first quarter total revenue increases to $5.3 million

Labopharm first quarter total revenue increases to $5.3 million

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Labopharm monetizes future royalty payment stream for RYZOLT through subsidiary

Labopharm monetizes future royalty payment stream for RYZOLT through subsidiary

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

Labopharm receives notice about Activis' ANDA for OLEPTRO

Labopharm receives notice about Activis' ANDA for OLEPTRO

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm third quarter total revenue increases to $9.6 million

Labopharm third quarter total revenue increases to $9.6 million

Single injection of morphine to fight persistent pain reduces testosterone level: Research

Single injection of morphine to fight persistent pain reduces testosterone level: Research

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Cipher reports net revenue of $1.1 million for 2010 third quarter

Cipher reports net revenue of $1.1 million for 2010 third quarter

Labopharm, Paladin Labs expand commercial relationship

Labopharm, Paladin Labs expand commercial relationship